Oncobeta chosen as one of the Trailblazing Companies to Watch in 2019

OncoBeta- A Pioneer And Innovator In The Epidermal Radioisotope Therapy Sector

Skin is the largest organ of the body and represents the first barrier between the inside of the body and external influences like mechanical stress or radiation for example. However, long-term influences on the skin might lead to irreparable damage that can develop into skin cancer e.g. Non-Melanocytic Skin Cancer (NMSC). NMSC is the world’s most common type of cancer. 90% of NMSC cases are seen on the face or head. In most cases, NMSC is not fatal, but if left untreated, it can destroy local tissue and also cause disfigurement or dysfunction, which impairs quality of life.

Innovating in this field, to provide painless and easy treatment solutions is OncoBeta. Headquartered in Garching Technology and Founders Center GATE near Munich, OncoBeta is a privately held medical device company. They specialize in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy). Read More